S.3560 - Recalcitrant Cancer Research Act of 2012
A bill to provide for scientific frameworks with respect to recalcitrant cancers.
Loading Bill Text
Rollover any line of text to comment and/or link to it.
Mr. WHITEHOUSE (for himself, Mr. LUGAR, Ms. MIKULSKI, Mr. GRASSLEY, Mr. AKAKA, Ms. COLLINS, Mr. REED, Mr. PRYOR, Ms. STABENOW, Mr. BROWN of Massachusetts, Mr. LAUTENBERG, Mr. BLUNT, Mr. BROWN of Ohio, Mr. RUBIO, Mr. BLUMENTHAL, Mr. WICKER, Mr. TESTER, and Mr. WARNER) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsCommentsClose CommentsPermalink
SECTION 1. SHORT TITLE.
SEC. 2. SCIENTIFIC FRAMEWORK FOR RECALCITRANT CANCERS.
‘SEC. 417G. SCIENTIFIC FRAMEWORK FOR RECALCITRANT CANCERS.
‘(1) IN GENERAL- For each recalcitrant cancer identified under subsection (b), the Director of the Institute shall develop (in accordance with subsection (c)) a scientific framework for the conduct or support of research on such cancer.CommentsClose CommentsPermalink
‘(II) the fundamental biologic processes that regulate such cancer (including similarities and differences of such processes from the biological processes that regulate other cancers); andCommentsClose CommentsPermalink
‘(ii) SCIENTIFIC ADVANCES- The identification of relevant emerging scientific areas and promising scientific advances in basic, translational, and clinical science relating to the areas described in subclauses (I) and (II) of clause (i).CommentsClose CommentsPermalink
‘(iv) COORDINATED RESEARCH INITIATIVES- The identification of the types of initiatives and partnerships for the coordination of intramural and extramural research of the Institute in the areas described in clause (i) with research of the relevant national research institutes, Federal agencies, and non-Federal public and private entities in such areas.CommentsClose CommentsPermalink
‘(v) RESEARCH RESOURCES- The identification of public and private resources, such as patient registries and tissue banks, that are available to facilitate research relating to each of the areas described in clause (i).CommentsClose CommentsPermalink
‘(B) IDENTIFICATION OF RESEARCH QUESTIONS- The identification of research questions relating to basic, translational, and clinical science in the areas described in subclauses (I) and (II) of subparagraph (A)(i) that have not been adequately addressed with respect to such recalcitrant cancer.CommentsClose CommentsPermalink
‘(C) RECOMMENDATIONS- Recommendations for appropriate actions that should be taken to advance research in the areas described in subparagraph (A)(i) and to address the research questions identified in subparagraph (B), as well as for appropriate benchmarks to measure progress on achieving such actions, including the following:CommentsClose CommentsPermalink
‘(4) PUBLIC NOTICE- With respect to each scientific framework developed under subsection (a), not later than 30 days after the date of completion of the framework, the Director of the Institute shall--CommentsClose CommentsPermalink
‘(A) submit such framework to the Committee on Energy and Commerce and Committee on Appropriations of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions and Committee on Appropriations of the Senate; andCommentsClose CommentsPermalink
‘(1) IN GENERAL- Not later than 6 months after the date of the enactment of this section, the Director of the Institute shall identify two or more recalcitrant cancers that each--CommentsClose CommentsPermalink
‘(2) ADDITIONAL CANCERS- The Director of the Institute may, at any time, identify other recalcitrant cancers for purposes of this section. In identifying a recalcitrant cancer pursuant to the previous sentence, the Director may consider additional metrics of progress (such as incidence and mortality rates) against such type of cancer.CommentsClose CommentsPermalink
‘(c) Working Groups- For each recalcitrant cancer identified under subsection (b), the Director of the Institute shall convene a working group comprised of representatives of appropriate Federal agencies and other non-Federal entities to provide expertise on, and assist in developing, a scientific framework under subsection (a). The Director of the Institute (or the Director’s designee) shall participate in the meetings of each such working group.CommentsClose CommentsPermalink
‘(1) BIENNIAL REPORTS- The Director of NIH shall ensure that each biennial report under section 403 includes information on actions undertaken to carry out each scientific framework developed under subsection (a) with respect to a recalcitrant cancer, including the following:CommentsClose CommentsPermalink
‘(2) ADDITIONAL ONE-TIME REPORT FOR CERTAIN FRAMEWORKS- For each recalcitrant cancer identified under subsection (b)(1), the Director of the Institute shall, not later than 6 years after the initial development of a scientific framework under subsection (a), submit a report to the Congress on the effectiveness of the framework (including the update required by subsection (a)(3)(A)(ii)) in improving the prevention, detection, diagnosis, and treatment of such cancer.CommentsClose CommentsPermalink
‘(e) Recommendations for Exception Funding- The Director of the Institute shall consider each relevant scientific framework developed under subsection (a) when making recommendations for exception funding for grant applications.CommentsClose CommentsPermalink